A well-known injectable birth control method is under fire after multiple studies linked it to a specific kind of brain tumor, and now, lawsuits are piling up against the drugmaker. […] The post ...

Currently, a multidistrict litigation against Pfizer (NYSE: PFE) is underway on behalf of women who claim to have developed meningiomas after receiving four or more consecutive injections of ...

Pfizer Inc. (NYSE: PFE) announced today the completion of a global, ex-China, licensing agreement with 3SBio, Inc. (01530.HK) ...

Studies have linked a type of injectable birth control with meningioma, while the manufacturer says the claims are “without ...

Pfizer (PFE) stock in focus as company faces lawsuits over its alleged failure to warn about brain tumor risks linked to Depo ...

A 30-page federal lawsuit has been filed in the U.S. District Court of the Eastern District of Texas against Eastman Chemical ...

Depo-Provera is a birth control shot that is injected every three months and features a type of progestin hormone called ...

Tevogen ('Tevogen Bio Holdings Inc.” or 'Company”) (Nasdaq: TVGN) today announced the signing of a letter of intent to lease a 17,428-square-foot facility in New Jersey. The facility, formerly ...

Diabetes progression indicators, including chronic kidney disease and prolonged diabetes duration, were associated with greater kidney cancer risk.

Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety concerns reported.

Pfizer and Astellas are underlining the benefits of Xtandi as part of a combination therapy for certain patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC) with an overall | In ...